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Motor neuron diseases (MNDs) are a group of neurodegenerative disorders with involvement of upper and/or
lower motor neurons, such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), progressive
bulbar palsy, and primary lateral sclerosis. Recently, we have mapped a new locus for an atypical form of ALS/
MND (atypical amyotrophic lateral sclerosis [ALS8]) at 20q13.3 in a large white Brazilian family. Here, we report
the finding of a novel missense mutation in the vesicle-associated membrane protein/synaptobrevin-associated
membrane protein B (VAPB) gene in patients from this family. Subsequently, the same mutation was identified in
patients from six additional kindreds but with different clinical courses, such as ALS8, late-onset SMA, and typical
severe ALS with rapid progression. Although it was not possible to link all these families, haplotype analysis suggests
a founder effect. Members of the vesicle-associated proteins are intracellular membrane proteins that can associate
with microtubules and that have been shown to have a function in membrane transport. These data suggest that
clinically variable MNDs may be caused by a dysfunction in intracellular membrane trafficking.
Introduction
The motor neuron diseases (MNDs) are a heterogeneous
group with involvement of upper and/or lower mo-
tor neurons. Spinal muscular atrophy (SMA [MIM
253300]) is one of the most common autosomal reces-
sive disorders in childhood, with an incidence of 1 in
6,000–10,000 births. SMA is caused by degeneration of
the anterior horn cells in the spinal cord associated with
muscle paralysis and atrophy. On the basis of age at
onset and clinical severity, SMA is subdivided into three
forms: SMA-I (MIM 253300), SMA-II (MIM 253550),
and SMA-III (MIM 253400). An autosomal dominant,
familial, late-onset SMA (MIM 182980) has also been
reported (Richieri-Costa et al. 1981). More recently, an
X-linked recessive form of SMA with slow progression
was mapped to Xq13.1-q21 (Takata et al. 2004).
Amyotrophic lateral sclerosis (ALS) is a heterogene-
ous, progressive, upper and lower motor neuron de-
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generative disease characterized by loss of motor neu-
rons in the spinal cord, brainstem, and motor cortex.
The combination of both upper and lower motor neu-
ron loss and pyramidal tract degeneration creates a
picture of progressive weakness with skeletal muscle
wasting and a fatal disease course of !5 years. Ap-
proximately 10% of all cases are familial (FALS), and
nine loci have been associated with this disease. To date,
mutations in only three genes have been found to be
associated with FALS. ALS1 (MIM 105400) was first
identified as an adult autosomal dominant disease as-
sociated with mutations in the Cu/Zn superoxide dis-
mutase gene (SOD1) on chromosome 21 (Rosen et al.
1993). More than 100 mutations in this gene have been
found in familial and sporadic cases of ALS. SOD1 cat-
alyzes the conversion of superoxide radicals to molec-
ular oxygen and hydrogen peroxide.
The exact relationship of this activity to the disease
process remains uncertain, since some of the disease-
associated mutations retain normal levels of enzyme ac-
tivity. ALS2 (MIM 606352) is a juvenile autosomal re-
cessive disorder with slow progression and is associated
with mutations in the Alsin gene on chromosome 2
(Hadano et al. 2001; Yang et al. 2001). Mutations in
this gene have also been associated with spastic para-
plegia (Eymard-Pierre et al. 2002; Gros-Louis et al.
2003), showing a clinical heterogeneity. The ALS4 form
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Figure 1 Mapping of the VAPB locus and mutation analyses. a, Pedigree from the first family reported with a diagnosis of ALS/MND
(an asterisk [*] indicates DNA was available). b, VAPB locus at 20q13.3. Recombinant events reduced the region to 1.5 Mb, between marker
D20S430 and the TUBB1 gene.
is a rare juvenile autosomal dominant disorder with
slow progression, pyramidal signs, and severe muscle
wasting, associated with mutation of the sentaxin gene
(SETX [MIM 608465]) (Chen et al. 2004). SETX en-
codes a novel DNA/RNA helicase. It is interesting that
some mutations in SETX lead to ataxia-oculomotor
apraxia type 2 (AOA2), an autosomal recessive disorder
(Moreira et al. 2004).
Recently, we mapped a new locus for ALS/MND at
20q13.3 (ALS8 [MIM 608627]) in a large white Bra-
zilian family with 28 affected members distributed
across four generations (fig. 1a) (Nishimura et al. 2004).
ALS8 is an autosomal dominant slowly progressive
disorder characterized by fasciculation, cramps, and
postural tremor. Recombinant events in the marker
D20S430 and the TUBB1 gene allowed us to locate the
responsible gene within a region of 1.5 Mb. A missense
mutation was found in the vesicle-associated membrane
protein (VAMP)/synaptobrevin-associated membrane
protein B gene (VAPB) in all patients of this family, as
well as in six additional families with a different di-
agnosis. Although we were not able to link these fam-
ilies, the historical data pointed to a common Portu-
guese ancestor, indicating that they might belong to a
large genealogy with 1200 affected patients and at least
1,300 normal relatives.
Patients, Material, and Methods
Families
We studied seven kindreds with patients who were
affected by an MND but had different clinical courses:
three had late-onset slowly progressive atypical ALS,
three showed a late-onset SMA (type Finkel [MIM
182980]), and, in one kindred, some patients had typical
ALS, whereas others had an atypical form of ALS. The
first family was already reported in the mapping of the
ALS8 locus (fig. 1b) (Nishimura et al. 2004). DNA from
affected subjects and from normal controls was obtained
after informed consent was given. The controls were
selected on the basis of sex, age, and race.
Fine Mapping of ALS/MND Variant
To identify the gene involved in this form of late-onset
MND, we first analyzed the genes located at 20q13.3,
flanking the markers D20S430 and D20S173. We
searched the public databases in MapView at the Na-
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tional Center for Biotechnology Information and com-
pared them with the Ensembl Genome database.
Genomic PCR
We performed PCR amplification of the region con-
taining both exons and intron-exon boundaries in the
candidate-region genes. Genomic DNA was obtained
from peripheral blood and was subsequently subjected
to amplification using Taq DNA polymerase (Invitrogen)
and comprising 35 cycles of 30 s at 95C, 30 s at 58C,
and 30 s at 72C followed by an extension of 6 min.
The oligonucleotide primers for the VAPB gene were
designed using Primer 3.0. The PCR products were an-
alyzed by SSCP and by direct sequencing using the Amer-
sham Mega Bace 1000 DNA Sequencers.
Multiple Alignments
The multiple amino acid sequence alignment was per-
formed using the ClustalW program. We included the
VAPB amino acid sequence from Homo sapiens, Mus
musculus, and Rattus norvegicus; VAPA amino acid
sequence from H. sapiens; and VAP-33 amino acid se-
quence from Aplysia californica, as well as VAP hom-
ologues and isoforms of VAPB in Drosophila melano-
gaster and Saccharomyces cerevisiae.
VAPB Models
Two VAPB structural models were generated for nor-
mal and mutant proteins, by use of the 3D-PSSM server
and the UCLA-DOE fold recognition server (top solu-
tion score of 62), on the basis of the major sperm protein
(MSP) structure of Ascaris suum (Protein Data Bank
code 1MSP) (Bullock et al. 1996; Kelley et al. 2000;
Mallick et al. 2002). The top five solutions were from
the same family of immunoglobulin-like folds.
Cell Culture and Expression Constructs
HEK293 cells were maintained in Dulbecco’s modified
Eagle’s medium (D-MEM) with glucose, L-glutamine,
and 10% fetal calf serum and were transfected by stan-
dard calcium-phosphate precipitation. Primary hippo-
campal neurons were prepared from E18-19 rat em
bryos, as described elsewhere (Bekkers and Stevens
1989) and were transfected by a modified form of cal-
cium-phosphate precipitation (Kohrmann et al. 1999).
Fluorescent images of living cells were acquired on an
Olympus IX70 controlled by OpenLab software (Im-
provision) with the use of a Hammamtsu ORCA ER
camera.
The full-length coding sequence of VAPB was gener-
ated by PCR on mouse brain cDNA (C57/BL6) and Pfu
polymerase. Restriction sites for EcoRI and BamHI were
incorporated into the PRC primers and were used to
insert the cDNA into pEGFP-C1 (Clontech). The P56S
mutation was introduced by PCR using Pfu and the
primers 5′-TACTGCGTGCGGTCCAACAGTGGGG-3′
and 5′-CCCCACTGTTGGACCGCACGCAGTA-3′. For
colocalization studies, cells were cotransfected with
pEGFP-C1, pDsRed2-C1, pDsRed-ER, or pGolgi-ECFP
(Clontech).
Results
Clinical Evaluation
The clinical evaluation of 24 patients from seven kin-
dreds is summarized in table 1. In the studied cases, age
at onset varied from 25 to 55 years, and both sexes were
equally affected. Symptoms and signs, such as muscular
cramps, fasciculation, and progressive limb and trunk
weakness with decreased or absent deep-tendon reflexes,
were present in all patients. However, a marked inter-
and intrafamilial heterogeneity was seen. Three phe-
notypes could be distinguished: late-onset SMA, atypical
ALS, and typical ALS. SMA was seen in eight patients,
with an average age at onset of 46 years (range 36–55
years) and average age at ascertainment of 54 years
(range 43–62 years). There was no bulbar or pyramidal
involvement in this group. Atypical ALS was seen in 15
patients, with an average age at onset and age at ascer-
tainment of 38 years (range 25–44 years) and 50 years
(range 42–60 years), respectively. Bulbar signs (dyspha-
gia) were seen in 11 (73%) subjects. After 2–60 years
of progression, 5 (33%) of the 15 patients were wheel-
chair bound. In addition to SMA manifestations, these
patients were classified as having ALS because of the
presence of bulbar and pyramidal signs—but also as hav-
ing atypical ALS because of essential tremor, present in
all these patients, which is not seen in typical ALS. Fi-
nally, five patients from kindred 4 (fig. A1 [online only])
showed a progression characteristic of typical ALS, with
a life span of !5 years after onset and a combination of
pyramidal and peripheral motor neuron involvement. It
is interesting that, in this same family, there are at least
six patients with a slow progressive course with symp-
toms and signs comparable to atypical ALS.
Identification of a Missense Mutation in the VAPB
Gene
We had previously found linkage at 20q13.3 within
an interval of 2.7 Mb, using microsatellite markers
D20S430-D20S164-D2094-D20S171-D20S173 in
family 1 (fig. 1b). The maximum multipoint LOD score
was 7.45, found close to marker D20S164. Mutation
screening of candidate genes excluded the cathepsin Z
(CTSZ), syntaxin 16 (STX 16), ATP synthase, epsilon
subunit (ATP5E), and tubulin b1 (TUBB1) genes. It is
notable that we found a polymorphism in the 3′ UTR
Table 1
Clinical Evaluation of Patients with VAPB Mutation in the ALS8 Locus
CHARACTERISTIC
FINDING IN PATIENT FROM KINDRED
F1 F2
F3
F4
F5
F6
F7
IV-1 IV-12a IV-13 IV-14 IV-16 IV-17 IV-20 IV-32 IV-33 IV-34 IV-37 IV-1 IV-23 III-4 IV-12b V-13 IV-14 VI-26 VI-91 VI-93 VI-97 VI-96 VI-119 IV-14
Age (years) 42 50 49 47 44 42 55 56 49 45 50 60 57 58 56 49 58 51 62 48 61 55 43 52
Age at onset (years) 31 40 43 45 41 30 25 41 44 37 37 37 40 38 52 38 48 47 52 44 55 45 36 40
Progression (years) 11 10 6 2 3 12 30 15 5 8 13 23 17 20 4 11 10 4 10 4 6 10 7 12
Fasciculation                        
Cramps               ?         
Tremor                        
DDS                        
DPS                        
Wheelchair (years)  48 49    48 56    54          52  
Decreased/absent DTR                        
Bulbar signs                        
Pyramidal signs                     
Muscle atrophy      D P/D P/D  P/D P/D P/D P P P P P/D  P  P P P P
SMA                        
Atypical ALS                        
Typical ALS                        
NOTE.—Fp family; DDSp decreased distal strength; DPSp decreased proximal strength; DTRp deep-tendon reflexes; Pp proximal; Dp distal; p positive finding; p negative
finding.
a Survival of 10 years.
b Survival of 4 years.
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Figure 2 Analyses of VAPB gene. a, Chromatogram showing the mutation in VAPB coding sequence and normal control. b, Segregation
of the P56S mutation in heterozygous patients and normal controls (homozygous). The HaeIII enzyme cuts in several fragments, producing one
major allele of 179 bp in normal subjects and one allele of 207 bp in heterozygous patients. c, Partial amino alignment of the VAP homologues
genes. Gaps were introduced for optimal alignment. Lengths of each partial protein are indicated. The amino acid sequence FKVKTTAPRX-
YCVRPNS is highly conserved (blue), and the proline is indicated (red). d, Haplotype analysis of three kindred studied. All the patients have
a common haplotype (red), which was not present in normal relatives (green). e, VAPB models. The top part of the b sandwich is made of
green b strands, and the bottom part is made of red strands. Wild type induces a kink and splits half of the strand into the top part of the
sandwich (green) and the other half of the strand into the bottom part (red). The P56S mutation disrupts the hydrogen bonds between strands
on the same sheet of the b sandwich, favoring new hydrogen bonds that move the bottom half to the opposite side of the b sandwich.
of the TUBB1 gene, which was present in almost all
patients but which was subsequently also found in Bra-
zilian normal controls. Since RT-PCR analysis did not
show any alteration in the expression of TUBB1, it was
then used as an intrafamilial marker. In addition, this
polymorphism reduced the interval to 1.5 Mb between
the marker D20S430 and the TUBB1 gene. This region
contains nine genes (a Z-DNA binding protein gene; a
prostate androgen–induced RNA; an oncogene; and
genes encoding a protein phosphatase, an aminopepti-
dase-like protein, a protein involved in imprinting, a
Drosophila-like protein, and two proteins involved in
intracellular trafficking) and seven hypothetical or pre-
dicted genes.
Mutation screening in these candidates genes led to
the identification of a CrT substitution in exon 2 of the
VAMP/synaptobrevin-associated membrane protein B
(VAPB) gene (fig. 2a). This mutation at nucleotide 166
removes a HaeIII restriction site and results in a substi-
tution of the conserved proline for a serine at codon 56
(Pro56Ser, or P56S) (fig. 2b) This proline is conserved
in several species, such as H. sapiens, M. musculus, R.
norvegicus, A. californica, D. melanogaster, and S. cer-
evisae (fig. 2c). This mutation was present in all affected
members of family 1 but not in unaffected relatives or
in 400 chromosomes of unrelated normal controls. Sub-
sequently, we found the same mutation in 22 patients
from six additional large Brazilian kindreds with inter-
and intrafamilial clinical heterogeneity (fig. A1 [online
only]). Although it was not possible to link all these
families, the haplotype analysis with nine polymorphic
markers flanking the VAPB gene suggests a common
ancestor and, therefore, a founder effect (fig. 2d).
Characterization of VAPB
The VAPB protein has three structural domains. The
first 150 residues constitute an MSP domain conserved
between all VAP family members (Weir et al. 1998;
Nishimura et al. 1999). The central region of the pro-
tein contains an amphipathic helical structure and is
predicted to form a coiled/coil protein-protein interac-
tion motif and a hydrophobic carboxy terminus that acts
as a membrane anchor (fig. 1b).
Using a three-dimensional model of VAPB based on
the nematode 1MSP dimer structure, we examined the
possible effect of this mutation on the protein structure.
In wild-type VAPB, P56 lies within a particularly highly
conserved motif, FKVKTTAPRRYCVRPNS, distal to
the dimerization face (fig. 2c). The serine substitution
would remove a kink between two short stretches of b
strand, switching the hydrogen-bond pattern from one
b sheet to another. This would make the strand more
flexible and would greatly disrupt the hydrogen bonds
between strands on the same sheet of the b sandwich,
perhaps favoring new hydrogen bonds that move the
bottom half of the strand to the opposite side of the b
sandwich (fig. 2e).
VAPB and the closely related VAPA proteins have been
shown to associate with intracellular membranes, in-
cluding the endoplasmic reticulum (ER) and the Golgi
apparatus (Soussan et al. 1999; Skehel et al. 2000). To
examine the effect of the P56S mutation in VAPB on the
localization of the protein and on cellular membranes,
wild-type and mutant VAPB was expressed as green fluo-
rescent protein (GFP) fusion proteins in two different
cell types, HEK 293 and primary cultured rat hippo-
campal neurons (fig. 3a). In comparison with ER-DsRed,
wild-type VAPB-EGFP predominantly localized to the
ER (Soussan et al. 1999) (fig. 3b). In contrast, the P56S
mutation dramatically disrupts the subcellular distri-
bution of the numerous protein-inducing intracellular
aggregates (fig. 3c), which do not accumulate the luminal
ER-DsRed or the Golgi apparatus marker (fig. 3d–3e).
Thus, the P56S mutation in VAPB does not seem to be
a normally functioning polymorphism.
Discussion
Here, we describe the identification of a missense mu-
tation in the VAPB gene in seven families with dif-
ferent diagnoses that range from typical ALS to mild
SMA. The VAMP-associated protein of 33 kD (VAP-
33) was first identified in A. californica (GenBank ac-
cession number Q16943) (Skehel et al. 1995). This pro-
tein is highly conserved in different species, with homo-
logues in yeast (SCS2 [GenBank accession number
P40075]), fly (DVAP-33A [GenBank accession number
AY060395]), mouse (Ensembl Genome accession num-
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ber ENSMUSP00000029026), rat (Ensembl Genome ac-
cession number ENSRNOP00000007554), and human
(VAPA and VAPB [Ensembl Genome accession numbers
ENSP00000217602 and ENSP00000265619]) (fig. 2c).
The localization of these proteins appears to differ
among the species. VAP proteins in mouse and SCS2 in
yeast are localized on intracellular membranes, partic-
ularly the ER compartment (Kagiwada et al. 1998; Sous-
san et al. 1999; Skehel et al. 2000). Ultrastructural and
biochemical analyses indicated that these VAP proteins
can associate with microtubules and are often found at
the junction between intracellular vesicles and cytoske-
letal structures (Soussan et al. 1999; Skehel et al. 2000).
In Drosophila, the DVAP-33A homologue seems to be
localized in the neuromuscular junctions. Male mutants
show severe locomotion defects and die early in larvae
development (Pennetta et al. 2002). Moreover, the pre-
synaptic microtubule assembly is severely compromised.
The VAPB has been shown to act during ER-Golgi
transport and secretion (Soussan et al. 1999; Foster
et al. 2000). It is possible that the mutation of the MSP
domain disrupts this function, leading to the accumu-
lation of transport intermediates in the form of cytosolic
membranous aggregates. Although the expression of the
mutant form of VAPB does not lead to gross changes
in ER structure, we cannot exclude the possibility that
more subtle perturbations in Golgi and ER membrane
systems are occurring in cells expressing the mutant
form of VAPB. Thus, the mutant VAPB protein may
compromise intracellular membrane transport and se-
cretion, which may subsequently lead to loss of extra-
cellular trophic signals or to disruption of intracellu-
lar processes that ultimately result in the loss of motor
neurons. It is also possible that VAPB is present on
membrane structures distinct from the ER and Golgi
and that the MSP mutation affects the accumulation of
the protein at these sites. It is notable that, in older
neuronal cultures, the closely related protein VAPA ac-
cumulates in additional areas distinct from ER and
Golgi markers (data not shown).
It was recently shown that VAPA acts as a membrane
receptor for lipid- and sterol-binding proteins (Weir et
al. 1998; Wyles et al. 2002). This interaction is partly
dependent on the MSP domain and might, therefore, be
disrupted by the mutation causing a perturbation in the
composition of intracellular membranes. Mutations in
the yeast SCS2 affect phospholipid metabolism and dis-
rupt the signaling pathway from the ER that regulates
inositol biosynthesis and the unfolded protein stress re-
sponse (Kagiwada et al. 1998; Loewen et al. 2003). This
raises the interesting possibility that the MSP domain
of VAPA and VAPB proteins serve both a structural and
signaling function. It is notable that the MSP has a
signaling function during fertilization in nematodes
(Miller et al. 2001). VAPA and VAPB proteins can form
multimeric protein complexes (Soussan et al. 1999; Fos-
ter et al. 2000; P.S., unpublished data). The P56S VAPB
mutation lies outside the dimerization face of the MSP
domain and most likely affects the protein’s association
with other polypeptides. The P56S mutation does not
seem to result in a complete loss of function of the MSP
domain, since the expression of a truncated form of the
protein lacking the entire MSP domain does not induce
the formation of similar intracellular aggregates (data
not shown).
VAPB is ubiquitously expressed (Nishimura et al.
1999), yet the P56S mutation reported here predomi-
nantly affects motor neurons. This selective vulnerabil-
ity also occurs with ALS-associated SOD-1, ALS2, and
SETX mutations, and several hypotheses might explain
this observation. Perhaps different types of cells do not
require the same amount of VAPB for survival, or VAPB
may have another function specific to as-yet unknown
neurons. P56S VAPB could interfere with the stability
of a VAPB-containing protein complex, and a haploin-
sufficiency or gain-of-function mechanism could result
in neurotoxicity and, consequently, in motor neuron
death.
MNDs are a heterogeneous group, and the subclas-
sification is difficult, particularly when the lower motor
neuron signs are the major evidence of the disorder. In
three kindreds, there were patients with pyramidal tract
or upper motor neuron signs comparable to ALS,
whereas, in others, the diagnosis was more similar to
late-onset SMA. It is not known why the same mutation
is responsible for different phenotypes in these families.
Intrafamilial clinical heterogeneity has been found for
several human disorders, including the FALS forms in
patients with ALS and SMA who belong to the same
family (Corcia et al. 2002). A mutation in the Dysferlin
gene was also found to cause distal Miyoshy myopathy
in some patients and proximal limb-girdle muscular
dystrophy type B in others from the same genealogy
(Illarioshkin et al. 1996; Weiler et al. 1996; Zatz et al.
2000, 2003). These findings suggest that modifier genes
or other factors probably play an important role in
modulating the clinical course in affected patients car-
rying the same pathogenic mutation.
In summary, our data strongly suggest that the P56S
mutation in a highly conservative domain of the VAPB
gene is responsible for a variable form of MND in seven
large Brazilian kindreds. These data bring new insight
to understanding the mechanisms underlying motor
neuron degeneration and may help provide novel ther-
apeutic targets to rectify genetic errors.
Figure 3 GFP expression in hippocampal neurons and HEK293 cell culture. a, Neurons and HEK cells expressing the VAPB wild type
(green). b, Using an ER marker (red), we observed a colocalization of the VAPB and ER compartment (yellow), as reported elsewhere (only
the colocalization is shown). c, P56S mutant disrupts the subcellular distribution, showing intracellular aggregates. d–e, P56S mutant does not
colocalize either with Golgi apparatus (blue) or with the ER (red).
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